Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study.
Nobukazu FujimotoAyumi AkamatsuChikara HondaMiki AokiYuichiro OhePublished in: Japanese journal of clinical oncology (2024)
The post-marketing incidence of TRAEs with nivolumab in patients with MPM has been evaluated, and no new safety signals were identified compared to the phase II clinical trial in Japan.